Ticker
$CRBU
1 catalyst touching CRBU in the last 60 days, newest first, each with the price move that followed.
- 82
Caribou halts allogeneic CAR-T programs, cuts workforce; explores strategic alternatives
Caribou's Board approved discontinuation of its two lead allogeneic CAR-T programs (vispa-cel and CB-011), a substantial workforce reduction, and initiated a formal process to explore strategic alternatives including merger, acquisition, or asset sale due to constrained financing conditions for CAR-T therapies. The company expects $15–19 million in restructuring charges and a CFO departure contingent on deal execution, signaling material business contraction and likely equity dilution or loss of value in any transaction.
CRBU ▼SEC 8-K · 6 Oct 2026, 20:07 UTC
Information only. AURA does not give buy or sell recommendations.